Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1999-08-20
2000-10-31
Spivack, Phyllis G.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
A61K 31435, A61K 314545
Patent
active
061403377
ABSTRACT:
The present invention provides methods of treatment of mental disorders comprising administering the anti-allergic medication loratadine or a metabolite thereof to reduce a patient's symptoms of a mental disorder.
REFERENCES:
patent: 4659716 (1987-04-01), Villiani et al.
patent: 5595997 (1997-01-01), Aberg et al.
patent: 5763183 (1998-06-01), Pesonen et al.
patent: 5912335 (1999-06-01), Bergsma et al.
Song et al., European Neuropsychopharmacology, 6:157-1162, 1996.
Bell, I.R., et al, "Is Allergic Rhinitis More Frequent in Young Adults With Extreme Shyness? A Preliminary Survey,." Psychosomatic medicine, 52:517-525, 1990.
Kagan, J., et al, "Temperament and Allergic Symptoms", Psychosomatic Medicine, 53:332-340, 1991.
Bell, I.R., et al, "Depression and Allergies : A Survey of a Nonclinical Population," Psychother Psychosom, 55:31, 1991.
Rorsman, B., et al, "Premorbid traits and Psychosomatic Background Factors in Depression : The Lundby study 1957-1972", Neuropsychobiology, 27:72-79, 1993.
Marshall, P.S., "Allergy and Depression : A Neurochemical Threshold Model of the Relation Between the Illnesses," Psychological Bulletin, 113:23-43, 1993.
Gauci, M., et al, "A Minnesota multiphasic Personality Inventory Profile of Women With Allergic Rhinitis," Psychosomatic Medicine, 55:533-540, 1993.
Rao, K.S., et al, "Duration of the Suppressive Effect of Tricyclic Antidepressants on Histamine-induced wheal-and-flare Reactions in Human Skin", J. Allergy Clin Immunol, 82:752-757, 1988.
Wood, K, et al, "Platelet Accumulation of Histamine in Controls, Depressed, and LithiumTreated Patients," J. Affective Disorders, 7:149-158, 1984.
Matussek, P, et al, "Aggression and allergic disorder in depressives", Journal of Psychosomatic Research, 1984; 28:205-211.
Matussek, P., et al, "Allergic Disorders in Depressive Patients," Comprehensive Psychiatry, 24:25-34, 1983.
Sanger, M., "The treatment of Anxiety and Depression in Then Allergic Patient", Annals of Allergy, 27:506-510, 1969.
Leonard, G, "Behavioral manifestations of Allergic Children", Annals of Allergy, 24:248-249, 1966.
Younes, R.P., et al, "Manic-depressive Illness in Children : Treatment with Lithium Carbonate," Journal of Child Neurology, 1:364-368, 1986.
Nasr, S., et al., "Concordance of Atopic and Affective Disorders," Journal of Affective Disorders, 3:291-296, 1981.
Shen et al., "Molecular Cloning and Expression of a 5-Hydroxytryptamine.sub.7, Serotonin Receptor Subtype," The Journal of Biological Chemistry, 263:18200-18204, 1993.
Gelernter et al., "Assignment of the 5HT7 Receptor Gene (HTR7) to Chromosome 10q and Exclusion of Genetic Linkage with Tourette Syndrome," Genomics, 26:207-209, 1995.
Thomas et al., "Unique allosteric regulation of 5-hydroxytryptamine receptor-mediated signal transduction by oleamide," Proc. Natl. Acad. Sci. USA, 94:14115-14119, 1997.
Lawler, et al., "Interactions of the Novel Antipsychotic Aripiprazole (OPC-14597) with Dopamine and Serotonin Receptor Subtypes," Neuropsychopharmacology, 20:612-637, 1999.
Rebecca A. Prosser, "Neuropeptide Y blocks serotonergic phase shifts of the suprachiasmatic circadian clock in vitro," Elsevier Brain Research, 808:31-41, 1998.
Jasper et al., "Cloning, expression and pharmacology of a truncated splice variant of the human 5-HT.sub.7 receptor (h5-HT.sub.7(b)," British Journal of Pharmacology, 122:126-132, 1997.
Kennaway et al., "Serotonin agonists mimic the phse shifting effects of light on the melatonin rhythm in rats," Elsevier, Brain Research, 737:301-307, 1996.
Traiffort et al., Interaction of mianserin, amitriptyline and haloperidol with guinea pig cerebral histamine H.sub.2 receptors studied with [.sup.125 I] iodoaminopotentidine, European Journal of Pharmacology, 207:143-148, 1991.
Roth et al., "Binding of typical and Atypical Antipsychotic Agents to 5-Hydroxytryptamine-6 and 5-Hydroxytryptamine-7 Receptors," The Journal of Pharmacology and Experimental Therapeutics, 268:1403-1410, 1994.
Wirz-Justice et al., "A Schizophrenic patient with an arrhythmic circadian rest-activity cycle," Elsevier, Psychiatry Research 73:83-90, 1997.
Urbina, et al. "5HT.sub.1A Receptor Agonist Differentially Increases Cyclic AMP Concentration in Intact and Lesioned Goldfish Retina. In Vitro Inhibition of Outgrown by Forskolin," Neurochem, Int. 29:453-460, 1996.
Pickard et al., "Serotonergic Innervation of the Hypothalamic Suprachiasmatic Nucleus and Photic Regulation of Circadian Rhythms," Biology of the Cell 89:513-523, 1997.
"Guidelines for controlled trials of drugs in migraine," International Headache Society Committee on Clinical Trials in Migraine, Cephalalgia 11, 1991.
Glen D. Solomon, "Therapeutic Advances in Migraine," J. Clin Pharmacol, 33:200-209, 1993.
Kikuchi et al., "Tetrahydrobenzindoles: Selective Antagonists of the 5-HT.sub.7 Receptor," Journal of Medicinal Chemistry, 42:533-535, 1999.
Nelson et al., "Cloning and Expression of 5HT7 Receptor from Xenopus laevis," Receptors and Channels, 3:61-70, 1995.
David Goldman, "Candidate Genes in Alcoholism," Neuroscience, 3:174-181, 1995.
Peter J. Goadsby, "Serotonin Receptors and the Acute Attack of Migraine," Neuroscience, 5:18-23, 1998.
Dupont et al., "Epinastine WAL 801CL) inhibits the electrical field stimulation-induced cholinergic contractionn in guinea pig and human airways in vitro," European Respiratory Journal 14:1068-1075, 1999.
Binder Gary
Iezzoni Domenic G.
Kreutner William
Lash Arnold
Schering Corporation
Spivack Phyllis G.
Wyatt Donald W.
LandOfFree
Methods for the treatment of mental disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for the treatment of mental disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for the treatment of mental disorders will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2052115